Tty Biopharm Company Limited · TPEX:4105
Tty Biopharm — Investor Presentation (April 2017)
74 slides from Tty Biopharm's investor presentation, April 2017
Slide 1: April, 2017
April, 2017
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, a
Slide 3: Liposomal & microsphere depot platform mission
We have been striving to extend liposomal & microsphere depot platform technologies for treatment of various diseases. Our Target is to improve health and quality of life through innovative, cost-effective therapeutics and specialty drugs. Our focus is on the “Unmet Medical Needs” in challenging dis
Slide 4: Company Overview
Company Overview Product Strategy as ee Product Pipeline EE as Manufacture Facilities Successful Product Categories a es In Progress Status Biotech Success WV ei WPT BRERA
Slide 5: 2016 revenue NTD 3.80 billion
2016- NTD 3.80 Billion, USD 117 Million 508 (March, 2017)
Slide 6: TTY Biopharm global leader in Super-Generic Drugs
TTY Biopharm is a global leader in Super-Generic Drugs and novel bio-drug development with strong growth potentials (targeting for 20% sales CAGR in 2014-19). TTY is Taiwan’s largest biotechnology conglomerate with the most completed biotechnology products pipeline including oncology drugs, new
Slide 7: Major Investments
Major Investments 轉投資主要架構 Global Taiwan 殷瀚 China EnhanX (67%) Asia • 臨床試驗開發暨行銷業 務推廣 • 研發開發暨行銷業務推 廣 東生華製藥 智擎生技 創益生技 TSH (56.48%) PharmaEngine (19.30%) CY Biotech (27.54%) 慢性病領域 • 新藥開發公司 • 益生菌及減肥藥開發 (CV/GI/Immune)之藥物 開發暨行銷業務推廣 榮港生技 ATB泰/ATB菲/越辦事處 WorldCo (100%) 40%/87%/100% • 藥物開發(Liver/ID/CNS) • 藥物
Slide 8: TTY 核心能力
TTY 核心能力 專業行銷能力 技術研發 國際大廠代工 創新改革 製程開發與 量產設計 世界級微脂體 技術平台 世界級微球 技術平台 8
Slide 9: Corporate Strategy 集團策略
Corporate Strategy 集團策略 專注 研發 領導腫瘤，感染 開發技術平台 & 自體免疫療法 (微脂體 & 微球) 治療 創新配方 & 國際，區域 & 在地 技術發展產品鏈 合作夥伴 (e.g., Pegylipo, Lipo-AB) 商業化 國際合作 9
Slide 10: Company Overview
Company Overview Product Strategy Product Pipeline EE _— Manufacture Facilities Successful Product Categories In Progress Status Biotech Success
Slide 11: Product Strategy
Product Strategy Trends for Pharmaceutical Industry Market Scope (Risk) Ar New Derivatives Special Formulation New Combination (Technology Platform/ Target Therapy) New Indication New Formulation = fGeneic | « Entry Barrier (Profit)
Slide 12: TTY Super Generics Pipeline
TTY Super Generics Pipeline 註：2017年2月底與國際大廠初步達成協議，2017年授權代工價格預期與2016年相當。 Products Indication(s) R&D (BE;BA+CT) ANDA (EU/USA) Caelyx/Doxil (註) (Lipo-Dox) 轉移性乳癌、 Approved 愛滋病引發之卡波西氏肉瘤、 多發性骨髓瘤、卵巢癌 Pegylipo 利時曼氏病(黑熱病)、骨髓移植 TW Approved 併發腎毒侵入性細菌感染、 Lipo-AB 愛滋病患者腦膜炎、腎功能不全 之菌種感染病患 Leuprolide 前列腺癌、子宮內膜異位症、
Slide 13: Pegylipo, Lipo-AB, Col103
Pegylipo Lipo-AB First Choice Multidrug-resistant Gram-negative Formulation Col103 Bacteria Serious Infection 150 Irreplaceable Option, TWNIH
Slide 14: Caelyx/Doxil/Pegylipo
Caelyx® /Doxil® /Pegylipo® Source : Thomson Reuters Mar./2017
Slide 15: Lipo-AB
Global Market: USD$440 Million Target:Worldwide 35~50% Concurrent renal The infected bursa Leishmaniasis toxicity invasive meningitis HIV bacterial infection patients Systemic fungal infection Uitte eng “MOHESUESAL sxmeeEmA HORTR MMAR
Slide 16: Leuprolide
s oe @ é " ee PN "950. Ve, Rts ee ee . sy > Rt? oe On we» Pat ees r 3 "9 6* oe a Management of Prostate Cancer Endomottionts B37 aie FEAR iE Specia Global 2014 Lupron/Leuprolide Market: USD$1.24 Billion Target:Worldwide 20~35% Central Precocious Uterine Fibroids Puberty SLR PATE BR )Vowruni “oe ae e
Slide 17: Specialty- Risperidone Injection
Specialty- Risperidone Injection Indication: Schizophrenia Global market: USD$960 Million Risperidone Beagle in vivo release Risperidone 9-OH-Risperidone ~@ Risperdal Consta_AKZT800 2 -® Risperdal Consta_AKZT800 14) 4-RPO_120523 enn 12 = E 40. = 10 2 } En i: i & I 4 Zz 24 to} 2 10 2 °
Slide 18: Specialty- SPL206
Specialty- SPL206 Indications: @ Acromegaly @ Severe diarrhea/flushing episodes associated with metastatic carcinoid tumors @ Profuse watery diarrhea associated with VIP-secreting tumors Synthesized by TTY TTY synthetic star polymers as a carrier!! RO RO. CH, Oo Oo =H R HY RO OR o* y| OR " Polymer L
Slide 19: Mechanism of LGIA10
Mechanism of LGIA10 GLP-1 and Diabetes Indication: Type Il Diabetes Mellitus Stimulates insulin release Incretin,GLP-1 ) Inhibits glucagon DPP-4 release enzyme inactivates GLP-1 MSG DPP- 4 inhibitors (drugs) block DPP-4 and decrease glucose Lowering of blood glucose
Slide 20: Specialty – Col103
Specialty – Col103 粗分類 常見抗藥性菌株 Fungus Gram negative MDR-GNB (GNB) CR-GNB Bacterial Gram positive MRSA (GPC) VRE Virus MDR-:multi-drug resistant MRSA: methicillin resistant Staphylococcus aureus CR-: carbapenem resistant VRE: vancomycin resistant Enterococcus 27
Slide 21: Col103
Col103 Global Market: 150M Source: Expert Rev Anti Infect Ther. 2012;10(8):917- 限用於一般抗生素無效， 934 且具多重抗藥性之革蘭氏 By Y_tambe - Y_tambe's file, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=49535 陰性菌之嚴重感染。 28
Slide 22: Company Overview
Company Overview 8 ee ee Product Strategy Product Pipeline Manufacture Facilities - - Wwerewse Successful Product Categories DP Ae In Progress Status Biotech Success
Slide 23: Corporate Strategy 集團策略
Corporate Strategy 集團策略 專注 研發 領導腫瘤，感染 開發技術平台 EnhanX Inc. & 自體免疫療法 (微脂體 & 微球) 2B3-201 治療 A new drug of Pegylated Liposomal Methylprednisolone Injection －Introduction of Multiple Sclerosis 創新配方 & 國際，區域 & 在地 －Introduction of Pegylated Liposomal 技術發展產品鏈 合作夥伴 Methylprednisolone Injection (2B3-201) －Devel
Slide 24: Introduction of MS’s MoA
Introduction of MS’s MoA Damaged nerve Dendrites Damaged > f / myelin 4 A j Axon Cell boay Normal nerve \ Myelin » Healthy myelin Synapses Nerve fibers Transmit nerve signals throughout brain, body
Slide 25: Introduction of MS
Introduction of MS MS: a chronic, autoimmune & neurodegenerative disorder Body’s own defensive system attacks myelin Inflammatory damage in the brain and spinal cord Loss of myelin and axons (scars at multiple sites) Neurologic disability 32
Slide 26: Introduction of MS
Introduction of MS Around 2.5 millions 34
Slide 27: Introduction of MS
Introduction of MS Four Classifications of MS Either one of the four classifications occurs in acute; it’s the target patients of 2B3-201. 不管屬於哪一個發病類型，只要是急性復發，就是2B3-201的target 病患。 35
Slide 28: Patients Distribution in US Market
Patients Distribution in US Market US Multiple Sclerosis Population (~400,000) Relapse-Remitting (RR) 2° Progressive (SP) 1° Progressive (PP) Progressive Relapsing 50%, ~200,000 34%, ~136,000 13%, ~50,000 (PR/B*), 3%, 14k Mild (42%) Moderate (36%) Severe (22%) Relapse Rate Relapse Rate *Benign MS ~8
Slide 29: Introduction of MS 介紹
Introduction of MS 介紹 患者出現可能為MS的病症 經McDonald標準判定是否患有MS Yes No 確診 其他診斷 治療選項根據病症程度：是否已嚴重到影響生活品質（例：無工作能力） Yes No 第一線治療的選擇根據病症的嚴重程度 較嚴重： 較輕微： Severity • 甲基培尼皮脂 (Methylprednisolone) • 口服培尼皮質醇 (Prednisolone) 1st-line 注射針劑 神經科醫師在第一線治療選擇給予輕 therapy 多數的神經科醫師在第一線治療選擇 微病狀的病人口服類固醇 給予病人針劑類固醇 2nd-line 促皮質素 (ACTH)
Slide 30: 2B3-201 Pipeline
2B3-201 Pipeline 2B3-201：Liposomal Methylprednisolone Injection (glutathione PEGylated liposomal methylprednisolone) 2014 - 2016 2017 2018 2019 2020 2021 2022 Phase I Phase I bridging study (lyophilized injection) Scientific advice from FDA & EMA Phase II/III in MS relapses (vs placebo) Phase II/III
Slide 31: Introduction of the Product
Introduction of the Product 2B3-201 120nm 39
Slide 32: 2B3-201 potential indications
Introduction of the Product 2B3-201’s potential indications Neuromyelitis Optica Uveitis Source: http://www.msdiscovery.org/news/news_synthesis/ 8147-neuromyelitis-optica-part-2-pathogenesis Source: https://www.uveitis.net/patient/anterior.php 40
Slide 33: Introduction of BBB
Introduction of BBB Tight junction Tight junction 72Yeoui BBR Sm
Slide 34: Introduction of BBB
Introduction of BBB B Brain capillary A Capillary (in general) Basal Membrane Fenestration (with intact basal membrane) be ane foot process Pa "7, Endothelial Endothelial cell Brain capillary endothelial cell | i + Kr pRB 0np2 BATH + T Abluminal (brain)
Slide 35: Introduction of BBB
Introduction of BBB Blood a b ce d e f Carrier - Receptor - Paracellular mediated mediated Adsorptive Active Diffusion transport transport transcytosis transcytosis efflux Endothelial cell Astrocyte end-feet Brain
Slide 36: Introduction of BBB
Introduction of BBB NO. TARGETING LIGANDS NOTE 1 Transferrin MBP-426, MBP-Y003 2 Melanotransferrin 3 Insulin 4 LDL 5 Angiopeps 6 Leptin 7 Thiamine 8 Glutathione 2B3-101, 2B3-201 9 Synthetic Opioid Peptides 10 RVG Peptide 11 Tetanus Toxin, Tet1 and G23 12 Diphteria Toxin 13 TAT peptide 45
Slide 37: Introduction of 2B3-201
Introduction of 2B3-201 Effective drug delivery to across the blood-brain barrier (BBB) 46
Slide 38: Preclinical Study
Preclinical Study 在大鼠實驗的結果顯示，在注射8小時後，在腦中MP的量，2B3-201超 過非微脂體的MP6倍以上。 47
Slide 39: Preclinical Study
Preclinical Study 2B3-201: 藥效驗證試驗 EAE-MOG mouse model of MS 48
Slide 40: Phase I Study (Solution)
Phase | Study (Solution) Phase | dose-escalation results Phase | dose-escalation results Pharmacokinetics Effect on lymphocytes @ Long circulation half-lie of 2B3-201 @ Rapid and sustained immunosuppressive effect [Pon 2ehiesioee. WPTZS hes) @ Lymphocyte count crossed baseline within 7 @ Reduced hig
Slide 41: Major existing choices for MS treatments
Introduction of MS Major existing choices for MS treatments (2014 Sales & Market Share in Value) MS Therapies “ABCRE” products represented 64% of 2% 6% the global MS market in value in 2014 7% 4% 2% 1% －Moderate efficacy and patients continue to relapse on therapy －Require frequent injections La
Slide 42: Potential Market Size: US Peak Revenue
Potential Market Size 2B3-201 US Peak Year Revenue – MS & Other Inflammatory Indications $1603.9M $1,600M $140.3M $1,400M $1343.2M $254.2M $117.9M $1,200M $213.6M $259.9M $1,000M Revenue $218.3M $800M $601.5M $600M $52.6M $95.3M $928.8M $400M $97.5M $776.1M $200M $348.3M $0M Second-Line, Target Pene
Slide 43: Potential Market Size Globally
Potential Market Size Globally Global estimation MS treatment market rising from $17.2 billion to $20 billion (YoY) from 2014 to 2024 (approx.), at a Compound Annual Growth Rate (CAGR) of 1.5%. Global existing MS treatment market value (USD,000) 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Slide 44: Development Strategies
Development Strategies 2B3-201’s strengths • 2B3-201 is a pegylated liposome which glutathione is attached on its lipid, while methylprednisolone as the main substance is encapsulated inside. • Compared with the standard of care, i.e., a free methylprednisolone, 2B3-201 is an one-shot intravenous
Slide 45: Multiple Indications (Pipeline)
Multiple Indications (Pipeline) Indications to Develop Market Potential Size Competitors Teva (2014) Biogen 1 Multiple Sclerosis (多發性硬化症) >21.5B EMD Serono Novartis 2 Uveitis (葡萄膜炎) (眼睛發炎) >0.531B Humira (2016) 3 Neuropathic Pain (神經性疼痛) >5.7B Pfizer (2011) 4 Osteoarthritis (骨關節炎) >5.335B Anika (201
Slide 46: Multiple Indications: TTY and 2-BBB
Multiple Indications Synergistic Effect TTY EnhanX 2-BBB Inc. 66.7% 33.3% US$ 12M • Formulation development and • Development of clinical trials • Marketing globally commercial manufacture MS is a critical disease especially Partner global pharma R&D formulation center of TTY has for whites. 2-BBB,
Slide 47: Management Team
Management Team Yu-Fang Hu Pieter J. Gaillard Yuan-Yi Chou 55
Slide 48: Scientific Advisory Board
Scientific Advisory Board 蔡清標 Fred Lublin Taipei,Taiwan (New York, USA) Ralf Linker Frederik Barkhof (Erlangen, Germany) (Amsterdam, Netherlands) 55
Slide 49: Company Overview
Company Overview et ee a ee Product Strategy Ses Product Pipeline Manufacture Facilities Successful Product Categories LP ee In Progress Status Biotech Success
Slide 50: Manufacture Facilities
Manufacture Facilities The only PIC/S GMP certified manufacture sites for high potency oncology, 2008/2013/2016 EMA, 2010/2014 Japan, 2013/2016 US FDA, 2013 Brazil, Australia High standard Validation of Equipment qualification/ Laboratory instruments qualification/ HVAC system/ Water system/ C
Slide 51: Facility inspections timeline
中壢廠 2008 2009 2010 2011 2012 2013 2014 2015 2016 EMEA EMEA Jordan Germany US FDA EMA Korea US FDA Japan Arabian Official Official Official Official Turkey Kazakhstan Official Brazil Japan MOH EMEA Official Official 58
Slide 52: Comply with PIC/S GMP and Taiwan FDA inspection
六堵廠 Comply with PIC/S GMP and Taiwan FDA inspection for non-cytotoxic or non-hormone 59
Slide 53: PMDA (Japan)
PMDA (Japan)
Slide 54: Company Overview
Company Overview eH Product Strategy SS Product Pipeline Ro aa) Manufacture Facilities Successful Product Categories In Progress Status Biotech Success
Slide 55: Singapore Hong Kong Philippines
Singapore Hong Kong Philippines Breast Cancer乳腺癌、Lymphoma惡性淋巴瘤、Soft tissue Sarcoma軟組織肉瘤、 Gastric cancer, GC胃癌、Lung cancer LC肺癌、Ovarian Cancer, OC卵巢瘤
Slide 56: Nigeria, Vietnam, Singapore
Nigeria 、Vietnam、 Singapore
Slide 57: Products, indications and markets
Products 產品名稱 Indications 適應症 Market(s) 行銷地區 Treatment of advanced breast cancer in postmenopausal women. (治療 Anazo 停經後婦女晚期乳癌) (安納柔膜衣錠) Adjuvant treatment of early breast cancer in hormone receptor positive Taiwan、Philippines post-menopausal women who have received 2 to 3 years of adjuvant tamoxifen
Slide 58: 47 oncology product licenses in 12 countries
TTY has successfully registered 47 oncology product licenses in 12 countries. Country UFur Oxalip Lipo-Dox Irino Asadin Gemmis Tynen Epicin Thado Anazo Folina Sulfin Total EU Austria 2 2 Thailand 1 1 1 1 1 1 1 7 Philippines 1 1 1 3 Vietnam 1 1 1 2 1 2 1 9 Hong Kong 1 1 1 2 2 3 10 Malaysia 1 1 1 1 1
Slide 59: Products, indications and markets
Products 產品名稱 Indications 適應症 Market(s) 行銷地區 Brosym C+S 適用於治療由感受性細菌所引起的下列感染：上、下呼吸道感染、上、下泌尿道 (博益欣) 感染、腹膜炎、膽囊炎、膽管炎及其他腹腔內感染、骨盆發炎、子宮內膜炎及其 Taiwan 他生殖道感染、以及創傷燙傷、手術後之二次感染。 唯一抗感染新療效付芳心要對鮑氏不動桿菌(AB菌)治療效果佳。 Cubicin 1. 治療下列感受性革蘭氏陽性菌引起的複雜皮膚和皮膚組織感染(cSSSI)： (救必辛注射劑) Staphylococcus aureus (包括methicillin-resistant i
Slide 60: D&C Resource Revenue
年度 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 品項 Revenue 1,519,680 1,773,420 2,067,360 1,786,500 2,098,500 2,158,500 2,307,540 2,384,220 2,738,956 3,344,262 (NTD,000) R&D Expense 197,550 200,040 238,650 290,040 384,360 366,750 289,530 283,470 236,398 230,192 (NTD,000) *D&C Resource Total Staf
Slide 61: Company Overview
Company Overview Product Strategy Product Pipeline Manufacture Facilities Successful Product Categories In Progress Status Biotech Success 7iY¥: Yoru BBE BR
Slide 62: Apply Date and Approval Date (Est.)
送件日期 預估領證日期 核可類別 Category NPD Code Apply Date Approval Date (Est.) 第二等級醫材 1 2016/6/1 2016/12/13 2017 Class II Medical Device ES0013 2 2017/1/1 2018 新成分新藥 NCE TT7016 3 2016/7/1 2018 新成分新藥 NCE PT2014
Slide 63: Company Overview
Company Overview CXS! i 86M Product Strategy = a am Product Pipeline A. Manufacture Facilities /SP EA i Successful Product Categories In Progress Status Biotech Success
Slide 64: Biotech Success Strategy (2017-2021)
Biotech Success Strategy (2017-2021) • 營銷發展 TS-1、Painkyl、Brosym(C+S)、Episil、Lonsurf、Aplidin進入營銷高峰期 Liposome Doxorubicin全球上市 Liposome Amphotericin B 全球合作上市完成 Risperidone PLGA Leuprolide Depot (含大陸市場) Colimycin 區域整合、雙向併購計畫 泰國子公司ABT IPO上市計劃 • 研發規劃 推進CDMO全球合作開發&接案 PLGA(微球)系列產品開發 持續
Slide 65: 歷年財務報表 (個體)
歷年財務報表 (個體) 2013 2014 2015 2016 Item (Actual) (Actual) (Actual) (Actual) NTD ,000 Amount % Amount % Amount % Amount % Net Sales 2,292,163 100% 2,384,207 100% 2,738,956 100% 3,344,262 100% Gross Profit 1,404,003 61% 1,411,875 59% 1,777,941 65% 2,217,286 66% Operating Expenses -1,121,548 -49% -1,144,4
Slide 66: 歷年財務報表 (合併)
歷年財務報表 (合併) 2013 2014 2015 2016 Item (Actual) (Actual) (Actual) (Actual) NTD ,000 Amount % Amount % Amount % Amount % Net Sales 3,110,092 100% 2,979,902 100% 3,195,218 100% 3,760,717 100% Gross Profit 2,049,211 66% 1,898,936 64% 2,183,144 68% 2,559,220 68% Operating Expenses -1,709,349 -55% -1,560,8
Slide 67: 2014-2015-2016 淨利比較 (個體)
2014-2015-2016 淨利比較 (個體) 各季淨利不含出售投資損益 單位：新台幣仟元 年度 2014 2015 2016 季度 稅前 稅後 稅前 稅後 稅前 稅後 上半年度 95,926 76,156 321,740 281,251 735,949 635,684 下半年度 284,325 219,680 552,446 453,717 696,088 557,640 全年合計 380,251 295,836 874,186 734,968 1,432,037 1,193,324 74
Slide 68: 2014-2015-2016 淨利比較 (個體)
2014-2015-2016 淨利比較 (個體) 各季淨利不含出售投資損益 單位：新台幣仟元 年度 2014 2015 2016 季度 稅前 稅後 稅前 稅後 稅前 稅後 上半年度 95,926 76,156 321,740 281,251 735,949 635,684 下半年度 284,325 219,680 552,446 453,717 696,088 557,640 全年合計 380,251 295,836 874,186 734,968 1,432,037 1,193,324 成長 2015成長數 比較 2016成長數 稅前 稅後 稅前 稅後 225,814 205,095 414
Slide 69: Earning Distribution 盈餘分配
Earning Distribution 盈餘分配 Year 2011 2012 2013 2014 2015 2016 Item Yield Rate (%) 0.22 1.25 1.91 2.39 3.86 3.71 P/E 45.00 44.24 41.65 33.23 18.61 21.35 Cash Dividend 0.30 1.40 2.00 2.50 3.50 3.80 (註) Stock Dividend 2.40 0.89 0.67 - - - Total 2.70 2.29 2.67 2.50 3.50 3.80 註：尚需股東會決議。 75
Slide 70: TTY三大法人持股2015
TTY三大法人持股2015 台灣東洋(4105)法人持股走勢圖 1/6→12/31變化 140 120 100 三大法人持股 80 2.39萬張(9.63%) 60 12/31 ■ 117.50 元 (東洋股價) ↓ 70,000 2,000 8.22萬張(33.09%) 60,000 1,000 50,000 40,000 0 外資持股 -1,000 30,000 20,000 -2,000 2.09萬張(8.39%) 12/31 ■ 61,258 張 (外資持股) ■ -62 張 (外資買賣超) ↓ 25,000 2,000 6.12萬張(24.63%) 20,000 1,000 15,0
Slide 71: TTY三大法人持股2016
TTY三大法人持股2016 台灣東洋(4105)法人持股走勢圖 1/4→12/30變化 140 130 三大法人持股 120 110 100 8.19萬張(32.93%) 90 12/30 ■ 102.50 元 (東洋股價) ↓ 73,000 3,000 7.42萬張(29.85%) 70,000 2,000 67,000 1,000 64,000 0 外資持股 61,000 58,000 -1,000 -2,000 6.10萬張(24.54%) 12/30 ■ 65,396 張 (外資持股) ■ 154 張 (外資買賣超) ↓ 22,000 20,000 6.53萬張(26.30%) 500
Slide 72: 3 Major Investors 20160104~20170331
3 Major Investors 20160104~20170331 台灣東洋(4105)法人持股走勢圖 2016/1/4→ 140 130 2017/3/31 Shift 120 110 3 Majors 100 8.19萬張(32.93%) 90 03/31 ■ 109.00 元 (東洋股價) ↓ 73,000 3,000 6.97萬張(28.02%) 70,000 2,000 67,000 1,000 64,000 0 Foreign Investor 61,000 58,000 -1,000 -2,000 6.10萬張(24.54%) 03/31 ■ 60,671 張 (外資持股)
Slide 73: 保險公司及政府基金持股
201504/201604保險公司及政府基金持股 持股情形 2015/4月 2016/4月 機構 持有股數 持股比例 持有股數 持股比例 保險公司 4,880,800 1.96% 11,339,000 4.56% 政府基金 817,021 0.33% 21,177,843 8.52% 合計 5,697,821 2.29% 32,516,843 13.08% 保險公司及政府基金持股變化 政府基金 保險公司 - 3,000,000 6,000,000 9,000,000 12,000,000 15,000,000 18,000,000 21,000,000 24,000,000 2016年4月 2
Slide 74: 72¥%run TT TENG Q Rae Tue yf © Pac @Y¥siorech Fw mC ®
72¥%run TT TENG Q Rae Tue yf © Pac @Y¥siorech 28 Fw mC ® tshbiopharm #3 SMERARRERES)] Bil ae 4E
TTY Biopharm Company — Investor Presentation (April 2017) on 6ix